11.02.15
A single-dose of nattokinase, as NSK-SD from Japan Bio Science Laboratory, appears to enhance fibrinolysis and anti-coagulation via several pathways simultaneously, according to a study published in Scientific Reports.
A double-blind, placebo-controlled cross-over nattokinase intervention study, the research was designed to determine the quantitative effects of a single-dose of NSK-SD nattokinase administration on coagulation/fibrinolysis parameters comprehensively in healthy male subjects. Carried out in 12 healthy young males, each subject was randomized to receive either a single-dose of 2,000 FU of nattokinase or placebo with subsequent crossover of the groups, following the baseline blood draw.
“The study results further add to the scientific evidence demonstrating the ability of NSK-SD nattokinase to provide thrombolysis and anti-coagulation benefits,” said Vince Hackel, president of JBSL-USA, Incorporated. “Simultaneously, the results show our continued efforts to provide an ever-growing foundation of research and clinical studies to customers and end-use consumers in search of a product that can help provide cardiovascular health benefits by lowering blood pressure and improving circulation.”
During the study, subjects donated blood samples at 2, 4, 6 and 8 hours following administration for analysis of coagulation/fibrinolysis parameters. As a result, D-dimer concentrations at 6 and 8 hours, and blood fibrin/fibrinogen degradation products at 4 hours after nattokinase administration elevated significantly (p < 0.05, respectively). Factor VIII activity declined at 4 and 6 hours (p < 0.05, respectively), blood antithrombin concentration was higher at 2 and 4 hours (p < 0.05, respectively), and the activated partial thromboplastin time prolonged significantly at 2 and 4 hours following nattokinase administration (p < 0.05 and p < 0.01, respectively). All the changes, however, were within the normal range. Therefore, a single-dose of nattokinase administration appears to enhance fibrinolysis and anti-coagulation via several different pathways simultaneously.
For more information: www.jbsl-net.com/english/index.html
A double-blind, placebo-controlled cross-over nattokinase intervention study, the research was designed to determine the quantitative effects of a single-dose of NSK-SD nattokinase administration on coagulation/fibrinolysis parameters comprehensively in healthy male subjects. Carried out in 12 healthy young males, each subject was randomized to receive either a single-dose of 2,000 FU of nattokinase or placebo with subsequent crossover of the groups, following the baseline blood draw.
“The study results further add to the scientific evidence demonstrating the ability of NSK-SD nattokinase to provide thrombolysis and anti-coagulation benefits,” said Vince Hackel, president of JBSL-USA, Incorporated. “Simultaneously, the results show our continued efforts to provide an ever-growing foundation of research and clinical studies to customers and end-use consumers in search of a product that can help provide cardiovascular health benefits by lowering blood pressure and improving circulation.”
During the study, subjects donated blood samples at 2, 4, 6 and 8 hours following administration for analysis of coagulation/fibrinolysis parameters. As a result, D-dimer concentrations at 6 and 8 hours, and blood fibrin/fibrinogen degradation products at 4 hours after nattokinase administration elevated significantly (p < 0.05, respectively). Factor VIII activity declined at 4 and 6 hours (p < 0.05, respectively), blood antithrombin concentration was higher at 2 and 4 hours (p < 0.05, respectively), and the activated partial thromboplastin time prolonged significantly at 2 and 4 hours following nattokinase administration (p < 0.05 and p < 0.01, respectively). All the changes, however, were within the normal range. Therefore, a single-dose of nattokinase administration appears to enhance fibrinolysis and anti-coagulation via several different pathways simultaneously.
For more information: www.jbsl-net.com/english/index.html